ReviewClinical management of drug–drug interactions in HCV therapy: Challenges and solutions
Under a Creative Commons license
open access
Abbreviations
HCV
hepatitis C virus
DAAs
direct-acting antivirals
HIV
human immunodeficiency virus
SPCs
summary of product characteristics
Peg
polyethylene glycol
BID
twice daily
AKR
aldo-ketoreductases
P-gp
P-glycoprotein
AUC
area under the plasma concentration vs. time curve
FDA
Food and Drug Administration
EMA
European Medicines Agency
TDM
therapeutic drug monitoring
CYP
cytochrome P450
ECG
electrocardiogram
UGT
UDP-glucuronosyltransferase
ACE
angiotensin converting enzyme
AT1
angiotensin II receptor
PDE5
phosphodiesterase type 5
BOC
boceprevir
TVR
telaprevir
RBV
ribavirin
IFN
interferon
Keywords
Drug interactions
Hepatitis C virus infection
Boceprevir
Telaprevir
Pharmacokinetics
Cited by (0)
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier Ireland Ltd.